Vaccine Contract Manufacturing Market

Vaccine Contract Manufacturing Market Overview

The global vaccine contract manufacturing market size, valued at USD 2.25 billion in 2025, is projected to reach USD 2.40 billion in 2026 and USD 4.75 billion by 2035, representing a CAGR of 7.9% during the forecast period 2026 to 2035.

To learn more about this report, request a free sample copy

The new research study consists of industry trends, detailed market analysis, market landscape of vaccine contract manufacturers, company competitiveness analysis, SWOT analysis, capacity analysis, demand analysis, and market forecast and opportunity analysis.

Vaccine contract manufacturing refers to manufacturing services provided by contract manufacturers to pharmaceutical product manufacturers for the large-scale production of vaccines. The increasing pipeline of vaccines targeting various infectious diseases, oncological and autoimmune disorders drive the demand for contract manufacturing services, especially for specialized vaccines such as mRNA and viral vectors. 

Vaccinations play a pivotal role in preventing serious illnesses. Recent advancements in vaccine technology, particularly with the mRNA vaccine during the COVID-19 pandemic, have marked  significant milestones. Breakthroughs from companies such as BioNTech, Pfizer and Moderna have introduced innovative approaches to address existing challenges of vaccine development. In 2023, more than 5 vaccines were approved by FDA including the first vaccine for the prevention of respiratory syncytial virus (RSV) and chikungunya.

The rise of FDA-approved vaccines and ongoing scientific advancements signals the transition of pharmaceutical companies towards a new era of vaccines. With this demand for vaccines, opportunities for CMOs specializing in vaccines are growing steadily. Since 2000, more than 130 vaccine CMOs have been established, reflecting the market expansion of contract service providers. Contract service providers have been focusing on increasing their in-house capabilities to offer a wider range of services to their clients, along with regulatory assistance. Competition among contract manufacturing organizations (CMOs) is intense, with access to cutting-edge tools and technologies being a crucial differentiator. Consequently, CMOs are expanding their capacities and capabilities to consolidate their positions in the market and meet the escalating demand for vaccines. With outsourcing becoming increasingly accepted as a viable and beneficial business model within this field, the global market for vaccine contract manufacturing is expected to witness remarkable growth during the forecast period.

The growth in this market is also driving the success for vaccine adjuvants companies, who are developing innovative adjuvants for the vaccine developers and manufacturers.

Vaccine Contract Manufacturing Market Segmentation Insights

The market research report presents an in-depth analysis of the various service providers that are involved in the vaccine manufacturing, across different segments, as defined in the table below:

Vaccine Contract Manufacturing Market: Report Attributes / Market Segmentations

One of the key objectives of this market report was to estimate the current market size, opportunity and the future market growth potential for the service providers in the vaccine CMO market, over the forecast period. Based on multiple parameters, likely adoption trends and through primary validations, we have provided an informed estimate on the market evolution during the forecast period, till 2035.

The market report also features the likely distribution of the current and forecasted opportunity for service providers in the global market across various segments, such as type of expression system used (mammalian, microbial and others), company size (small, mid-sized and large / very large) and key geographical regions (North America, Europe, Asia-Pacific and Rest of the World). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three vaccine contract manufacturing market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s evolution.

The opinions and insights presented in the market report were influenced by discussions held with stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

• Chief Executive Officer and Marketing Manager, Mid-sized Company, The Netherlands
• Chief Executive Officer, Mid-sized Company, Austria
• Director Corporate Development, Mid-sized Company, The US
• Ex-Director, Mid-sized Company, The US
• Director Pharmaceuticals, Large Company, France
• Director Business Development, Mid-sized Company, Germany
• Head of Business Development, Very Large Company, The Netherlands
• Senior Business Development Manager, Mid-sized Company, Germany 

Further, all actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.

Vaccine Contract Manufacturing Market Share Insights

Market Share by Type of Expression System Used

The vaccine contract manufacturing market is segmented into mammalian, microbial and other expression systems, based on the type of expression system used. Currently, the mammalian market segment captures maximum share (60%) of the overall market; and this trend is unlikely to change in the future as well. This can be attributed to the fact that vaccines produced in mammalian cells often exhibit higher biological activity and binding affinity compared to those produced in microbial cells or other expression systems. This is particularly important for vaccines intended for clinical use, where potency and efficacy are critical factors.

Market Share by Company Size

Based on the company size, the vaccine contract manufacturing market is segmented into small, mid-sized and large / very large companies. Currently large and very large companies capture the majority of the market share (92%) of the overall market; and this trend is unlikely to change in the future as well. This can be attributed to the fact that large and very large players have well-established facilities, which have been / are being integrated with vaccine manufacturing capabilities to improve operational efficiencies and reduce the manufacturing cost of vaccines.

Market Share by Key Geographical Regions

This segment highlights the distribution of the market opportunity across various geographies, namely North America, Europe, Asia-Pacific and rest of the world. According to our projections, Europe is likely to capture majority (51%) of the global vaccine contract manufacturing market share, and this trend is unlikely to change in the future as well. It is worth highlighting that the vaccine CMO market in rest of the world region is expected to grow at a relatively higher CAGR (21.8%), during the forecast period, till 2035.

Vaccine Contract Manufacturing Market Key Insights

The “Vaccine Contract Manufacturing Market (4th Edition), Industry Trends and Global Forecasts, till 2035” report features an extensive study of the current market landscape, market size and future opportunities associated with service providers within the vaccine CMO market, during the given forecast period. The market report highlights the efforts of several stakeholders involved in this rapidly emerging segment of the service providers industry. Key takeaways of the market report are briefly discussed below.

Competitive Landscape of Vaccine Contract Manufacturing Companies

The current market landscape features the presence of over 235 contract service providers offering a variety of services related to vaccine contract manufacturing; these include scale of operation, type of service offered, type of expression system used, and type of vaccine manufactured. Further, the vaccine CMO market features the presence of small, mid-sized and large and very large companies having the required expertise to offer contract manufacturing services across the globe.

Vaccine Contract Manufacturing Market Growth

The growth for vaccine manufacturing services is primarily driven by the increasing demand for vaccines, particularly COVID vaccine. As the prevalence of infectious diseases rises, there is a continuous global push towards the preventive healthcare measures, highlighting the need for efficient vaccine production. Vaccine contract manufacturing provides companies with the flexibility to scale up production to meet the increasing demand. Moreover, outsourcing manufacturing to specialized facilities allows companies to focus on research and development, thereby accelerating vaccine innovation. Furthermore, forging partnerships with contract manufacturers streamline the production process, ensuring prompt delivery of vaccines to the market.

Vaccine Contract Manufacturing Market Size

The global market opportunity for vaccine CMO market is currently estimated to be USD 2.40 billion. In terms of the type of expression system used, the market size for mammalian vaccine CMO market is anticipated to grow at a relatively higher CAGR of 7.9% during the forecast period, till 2035. The market growth is primarily fueled by the increasing prevalence of infectious diseases. As the demand for vaccines grows, pharmaceutical companies seek outsourcing partners with expertise in vaccine production to meet their manufacturing needs efficiently and cost-effectively.

Regional Analysis: Europe Holds the Largest Vaccine Contract Manufacturing Market Share

Presently, Europe holds the largest share (51%) of the market, owing to the increasing R&D investments and number of clinical studies pertaining to the development of vaccines along with the expansion of manufacturing facilities by various players in Germany. Further, the market value for vaccine contract manufacturing in Asia-Pacific is expected to grow at a relatively higher CAGR of 21.8% during the forecast period. 

Leading CMOs based in the Vaccine Contract Manufacturing Market

Examples of key vaccine CMOs (which have also been captured in this market report, arranged in alphabetical order) include AGC Biologics, Bharat Biotech, Biological E, BioReliance, Boehringer Ingelheim BioXcellence, Catalent, Charles River Laboratories, Cobra Biologics, Curia, Eurofins Amatsigroup, Eurogentec, GreenPak Biotech, Hong Kong Institute of Biotechnology, IDT Biologika, Lonza, Meridian Life Sciences, Syngene International, WuXi Biologics and Wockhardt.

Vaccine Contract Manufacturing Market Report Coverage

The market report presents an in-depth vaccine contract manufacturing market analysis, highlighting the capabilities of various service providers engaged in this industry, across different geographies. Amongst other elements, the market report includes:

• An outline of the systematic research methodology adopted to conduct the study on vaccine contract manufacturing industry, providing insights on the various assumptions, methodologies, and quality control measures employed to ensure accuracy and reliability of our findings.
• An overview of economic factors that impact the overall service providers in the vaccine contract manufacturing market, including historical trends, currency fluctuation, foreign exchange impact, recession, and inflation measurement.
• An executive summary of the insights captured during our research. It offers a high-level view on the current state of services offered by service providers for vaccine manufacturing and its likely evolution in the mid-long term.
• A general overview of vaccines contract manufacturing, highlighting details on various types of expression system used in the development and manufacturing of vaccines. Furthermore, briefly describing the overview of contract manufacturing with their advantages and rising need.
• A detailed review of the overall landscape of companies, offering contract services for the manufacturing of vaccines, along with information on year of establishment, company size, location of headquarters, type of service offered (analytical testing, cell line development / virus banking, fill / finish, formulation development, process development and regulatory consulting), scale of operation (preclinical, clinical and commercial), type of expression system used (avian, insect, mammalian, microbial and others) and type of vaccine manufactured (live attenuated vaccines, inactivated vaccines, DNA vaccines, RNA-based (COVID 19 vaccines), subunit vaccines, toxoid-based vaccines and others / unspecified).
• A company competitiveness analysis of key players in this domain, featuring an assessment based on their company strength (related to the experience of a contract manufacturer), portfolio strength (which takes into account scale of operation, type of vaccine manufactured, type of service offered, type of manufacturing / workflow, capabilities and number of facilities).
• Detailed profiles of the key service providers in the vaccine contract manufacturing market, based in North America. Each profile features a brief overview of the vaccine contract manufacturing service provider, along with information on location of headquarters, year of establishment, number of employees, leadership team, service portfolio, recent developments, and an informed future outlook.
• Detailed profiles of the key service providers in the vaccine CMO market, based in Europe. Each profile features a brief overview of the vaccine contract manufacturing service provider, along with information on location of headquarters, year of establishment, number of employees, leadership team, service portfolio, recent developments, and an informed future outlook.
• Detailed profiles of the key service providers in the vaccine contract manufacturing market, based in Asia-Pacific. Each profile features a brief overview of the vaccine contract manufacturing service provider, along with information on location of headquarters, year of establishment, number of employees, leadership team, service portfolio, recent developments, and an informed future outlook.
• A detailed analysis of the partnerships inked between stakeholders in the vaccine contract manufacturing industry, based on several parameters, such as year of partnership, type of partnership, therapeutic area, type of vaccine manufactured, type of partner and most active players (in terms of the number of partnerships signed) and regional distribution of partnership activity that have taken place in this domain, since 2020.
• A detailed analysis of several expansion initiatives undertaken by various vaccine contract manufacturers, since 2020, based on several relevant parameters, such as year of expansion, purpose of expansion (capacity expansion, capability expansion, new facility, geographical consolidation and geographical expansion), geographical location of expanded facility, amount invested and most active players (in terms of number of instances).
• A detailed analysis of the various mergers and acquisitions that have taken place within this industry, since 2018, based on several relevant parameters, such as year of agreement, type of deal, geographical location of companies, type of acquisition, type of biologic manufactured, therapeutic area and key value drivers.
• An estimate of the overall, installed capacity for manufacturing vaccines based on data reported by industry stakeholders in the public domain; it highlights the distribution of available vaccine production capacity on the basis of company size (small, mid-sized, large and very large firms), type of expression system used (mammalian, microbial and others) and key geographical regions (North America, Europe, Asia-Pacific). 
• An informed estimates of the annual commercial and clinical demand for vaccines, based on key geographical regions. 
• An insightful vendor selection framework analysis highlighting the parameters that should be considered when outsourcing vaccine manufacturing operations. The analysis was designed to enable stakeholder companies to evaluate a vendor for outsourcing the manufacturing operations.
• A detailed analysis capturing the key parameters and trends that are likely to influence the future of vaccine contract manufacturing, under a SWOT framework.
• An in-depth analysis of the factors that can impact the growth of vaccine contract manufacturing. It also features identification and analysis of key drivers, potential restraints, emerging opportunities, and existing challenges.
• A detailed estimate of the current market size and the future market growth potential of the vaccine contract manufacturing market over the next decade. Based on multiple parameters, such as likely adoption trends and through reliable secondary and primary validations, we have provided an informed estimate on the market evolution during the forecast period, till 2035. The report also features the likely distribution of the current and forecasted opportunity within the vaccine contract manufacturing industry. Further, in order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the market growth.
• Detailed projections of the current and future opportunity for service providers in the vaccine CMO market across types of expression system used, namely mammalian, microbial and others.
• Detailed projections of the current and future opportunity for service providers in the vaccine contract manufacturing market across company size, namely small, mid-sized and large / very large.
• Detailed projections of the current and future opportunity for service providers in the vaccine CMO market across different key geographical regions, namely North America, Europe, Asia-Pacific and rest of the world.

Recent Developments in Vaccine Contract Manufacturing Market

Several recent developments have taken place in the field of vaccine contract manufacturing. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

• In March 2026, Anixa Biosciences entered into a development and manufacturing agreement with Cytovance Biologics to produce cGMP clinical materials for its planned Phase II breast cancer vaccine.
• In March 2026, Centivax closed USD 37 million funding round to accelerate Phase II development of influenza vaccine.
• In February 2026, CEPI collaborated with Samsung Biologics for $20 million in order to develop a scalable, rapid manufacturing platform for outbreak-ready vaccines, leveraging CDMO expertise to bolster global pandemic preparedness.
• In January 2026, Novavax signed a licensing agreement with Pfizer for its Matrix-M adjuvant in up to two disease areas. Pfizer paid USD 30 million upfront, with up to USD 500 million in milestones and mid-single digit royalties, while Novavax will supply the adjuvant.
• In October 2025, GC Biopharma collaborated with Curevo Vaccine to secure contract manufacturing rights for amezosvatein, a recombinant shingles vaccine.

Author(s): Ronit Sharma and Tamanna Sharma